January 22, 2015
CTI Clinical Trial and Consulting Services Announces Ira Davis, MD has joined as Medical Director
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ January 22, 2015]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces Ira Davis, MD has joined as Medical Director. Dr. Davis has significant experience in the clinical development of pharmaceuticals and medical devices, including protocol development, execution, and analysis, as well as more than 30 years of clinical, academic, and industry experience in pediatrics and nephrology.
Prior to CTI, Dr. Davis held several global medical positions with Baxter International in their dialysis business unit. He spent nearly two decades at Case Western Reserve University Rainbow Babies and Children’s Hospital, where he held numerous academic and clinical positions, including Associate Professor of Pediatrics, Chief of Pediatric Nephrology, and Clinical Director of the Pediatric Dialysis and Renal Transplant Programs. He has contributed to numerous clinical trials, peer-reviewed articles, publications, and speaking presentations throughout his career.
Dr. Davis earned his Bachelor of Arts (cum laude), Masters of Science (Genetics), and Doctor of Medicine from the University of Minnesota.
“We’re fortunate that Ira Davis has joined CTI’s medical team,” said William Aronstein, PhD, MD, Vice President, Medical Affairs. “Beyond the extensive experience and broad medical knowledge he brings to us, he has shown himself to be a good fit with our culture, working well with our teams and clients.”
“Dr. Davis will play a significant role in our drug development, clinical trials, and health outcomes programs,” according to Lynn Fallon, President. “His clinical and industry expertise will be an important asset for both our clients and staff.”
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe, Latin America and Pac-Asia.